The study is investigating whether brentuximab vedotin in combination with two drugs is more suitable for treating this type of cancer than the two drugs alone.
Aim of the study
The purpose of this study is to compare the positive and negative effects of brentuximab vedotin (BV) as a treatment for diffuse large B-cell lymphoma (DLBCL).
Who can take part?
The participants in this study have diffuse large B-cell lymphoma (DLBCL) that has returned or has not improved under treatment.
Procedure
There are two treatment groups in this study: One group receives lenalidomide and rituximab with brentuximab vedotin (BV/R-L). The other group received lenalidomide and rituximab with a placebo (P/R-L). A placebo is a substance that contains no active ingredients and you are randomly assigned to one of the two treatment groups, as in a lottery. This is a double-blind study, which means that neither you, the investigator nor the study team will know which treatment you are receiving until the end of the study.
Compensation
None
Original study name
A randomized, double-blind, placebo-controlled, multicenter, phase 3 comparative study of brentuximab vedotin or placebo in combination with lenalidomide and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
BASEC number
2020-02340
Financial support from
Seagen Inc.